New beta-lactam/beta-lactamase inhibitor combinations are expanding options against multidrug‑resistant Gram‑negative infections. Yet the clinical promise of these agents will hinge on how health systems finance, position and deliver them. Reporting themes from a recent UK antimicrobial meeting underscore an agenda that is as much about stewardship architecture, regulation and funding models as it is about molecules.
AMR framed as a ‘supreme global threat’ and a pipeline under strain
Opening a national forum on antimicrobial development, the BSAC president called antimicrobial resistance a ‘supreme global threat’ requiring urgent clinical, scientific and policy response. The burden data remain sobering and unevenly distributed, while pressure on the development pipeline persists. ‘The pipeline is weak’, and further innovation is needed to stimulate it, despite initiatives such as the UK’s subscription‑style “Netflix” payment model for novel antibiotics and the EU’s emerging pull incentives.
- Global mortality: 1.14 million deaths were attributable to antimicrobial resistance in 2021.
- England surveillance: the English Surveillance Programme for Antimicrobial Utilisation and Resistance Report 2024 to 2025 reports a 13.1% rise in drug‑resistant bacteraemia between 2019 and 2024.
- Resistance share: more than one in five bacteraemia episodes due to bacteria of public‑health importance are resistant to key antibiotics (England).
- Pathogen mix (bloodstream infections, England, 2019-2024): Enterobacterales account for over 85% of antibiotic‑resistant cases; Escherichia coli drives roughly two‑thirds; Klebsiella pneumoniae shows the fastest growth, up nearly 40%; Gram‑positive bacteraemias remain comparatively stable.
One UK public‑health microbiology lead cautioned that ‘everything that we’re really worried about is not going in the right direction’. The unequal toll is evident across patient groups and communities, with implications for how national health systems and payers design access pathways.
- Population impacts: higher exposure among deprived communities and vulnerable groups.
- Clinical vulnerability: people with cancer experience substantially higher rates of Gram‑negative infections.
- System capacity constraints: variable access to rapid diagnostics and limited ability to deliver optimized pharmacokinetics at the bedside.
Against this backdrop, governments are being pressed to align national antimicrobial resistance action plans and surveillance obligations under the International Health Regulations with the practical realities on hospital wards, where clinicians juggle resistance risks, budgets and workforce gaps in real time.
Where new agents fit – and where gaps remain
Development continues to prioritise beta‑lactam/beta‑lactamase inhibitor (BL/BLI) combinations that address the WHO priority list of Gram‑negative pathogens. The introduction of avibactam has been described as a step change that ‘really revolutionised the beta‑lactamase inhibitor field’, while pathogen‑specific agents are addressing entrenched niches such as carbapenem‑resistant Acinetobacter. The strategic deployment question for hospitals and payers is how to use these agents earlier and more effectively without accelerating resistance or breaching stewardship commitments.
| BL/BLI or Related Agent | Primary activity window (illustrative) | Notable gaps/limits | Stewardship positioning |
|---|---|---|---|
| Cefepime/enmetazobactam | ESBL‑producing Enterobacterales; relative stability to AmpC and OXA‑48 | Limited activity against KPC producers | Carbapenem‑sparing option when ESBL suspected/confirmed |
| Aztreonam + avibactam | Metallo‑beta‑lactamase producers; aztreonam stable to MBLs while avibactam inhibits co‑produced enzymes across Ambler classes | Dependent on availability, diagnostics, and delivery optimization | Bridging combination when MBL mechanisms are likely |
| Sulbactam/durlobactam | Drug‑resistant Acinetobacter baumannii targeting class D oxacillinases | Narrow organism focus by design | Targeted therapy ‘filling an important gap in the therapeutic armamentarium’ |
| Meropenem/vaborbactam | KPC and AmpC producers | MBLs remain out of reach | Option for confirmed/suspected KPC epidemiology |
Hospitals also continue to weigh formulary breadth against stewardship controls, mindful that a broader armamentarium must be matched by diagnostic capability, dosing infrastructure and contractual arrangements that do not penalise appropriate but low‑volume use.
‘New antibiotics save lives’ – but timing and delivery matter
Composite clinical data over the past decade indicate mortality benefits with ceftazidime/avibactam and meropenem/vaborbactam in infections caused by KPC‑producing organisms. The stewardship dilemma is whether traditional gatekeeping delays access beyond the point of greatest benefit. As one antimicrobial stewardship lead put it, the message for hard‑to‑treat KPC infections is simple: new antibiotics save lives – but they must be deployed fast enough, in high‑risk patients, to change the trajectory of sepsis and organ failure.
| Delivery lever | Operational rationale | System enablers |
|---|---|---|
| Prolonged infusion for time‑dependent beta‑lactams | Maximises time above MIC for agents like ceftazidime/avibactam; ‘You should always be giving beta‑lactams over prolonged infusion if you can,’ | Infusion pumps, nursing workflows, pharmacy protocols |
| Renal dosing during acute illness | Avoid premature dose reductions in transient kidney injury to prevent underexposure | Dynamic renal function monitoring, pharmacist oversight |
| Therapeutic drug monitoring (TDM) | Aggressive PK/PD target attainment is protective against microbiologic failure and on‑therapy resistance emergence | Assays, lab turnaround, multidisciplinary review |
| Early, evidence‑based use | Outcomes may improve when new agents are not reserved solely for salvage | Protocols that align restriction with risk‑based triggers |
For health‑system leaders, these levers are no longer niche clinical preferences; they are design requirements for intensive‑care capacity planning, antimicrobial budgets and performance metrics tied to sepsis bundles.
The Pseudomonas problem and the case for earlier deployment
Pseudomonas aeruginosa concentrates the tension between timely access and resistance stewardship. There is no single rapid diagnostic test covering its full resistance repertoire, and the organism’s accessory genome and adaptive capacity allow resistance to emerge quickly, including during therapy. In a recent evaluation of ceftazidime/avibactam and ceftolozane/tazobactam for Pseudomonas aeruginosa infections, resistance emerged in approximately one in five patients during therapy.
- Diagnostic gap: fragmented assays mean mechanism‑level confirmation may lag treatment decisions.
- Treatment sequencing: use of newer BL/BLIs often occurs after other options fail, reducing the chance of success.
- Clinical question: ‘Are we really putting these agents in the best position to be successful if we’re only reserving them for salvage scenarios in organisms that are already highly evolved and have many underlying mechanisms of resistance?’
- Decision paradigm: ‘We have to shift then, the clinical decision away from potentially earlier detection and maybe earlier differences in treatment selection.’
That shift implies earlier escalation in selected high‑risk phenotypes, backed by governance arrangements that accept short‑term drug spend in exchange for fewer ICU days, fewer surgical complications and lower onward transmission.
Translating science into stewardship: service design and policy levers
Hospitals are being asked to move beyond narrow restriction policies toward strategic deployment grounded in diagnostics, dosing science and equity. That shift relies on predictable funding, workforce capacity and shared accountability across pharmacy, microbiology and clinical teams, and is increasingly shaped by national AMR strategies and oversight from bodies such as the UK’s National Institute for Health and Care Excellence.
| System/Policy area | Operational need | Practical examples |
|---|---|---|
| Formulary governance | Risk‑based access to new BL/BLIs with clear escalation/de‑escalation rules | Pathway triggers based on prior colonisation, local resistance rates, source of infection |
| Diagnostics and lab capacity | Mechanism‑aware testing with rapid turnaround; integration into order sets | Reflex panels for carbapenemase detection; stewardship‑lab huddles |
| Dosing infrastructure | Ability to deliver prolonged infusions and implement TDM where indicated | Smart‑pump libraries; pharmacist‑led PK services |
| Payment and procurement | Models that reward availability and appropriate use, not just volume | Subscription‑style purchasing and outcomes‑linked access agreements |
| Equity and access | Protocols that account for higher AMR exposure in deprived and vulnerable groups | Targeted diagnostic access; monitoring disparities in time‑to‑effective therapy |
| Data and feedback loops | Ward‑level reporting on resistance, time‑to‑active therapy, and on‑therapy resistance | Dashboards that inform iterative pathway updates |
For ministers and regulators, these service elements are becoming test cases for whether national AMR action plans can move from strategy documents to enforceable standards in everyday care under frameworks such as the revised International Health Regulations.
Clinical realities that shape outcomes in 2026
- Pathogen priorities: development continues to mirror the WHO Bacterial Priority Pathogens List, with Gram‑negative threats dominating hospital burden.
- Pneumonia complexity: BL/BLIs have reduced lung penetration and can be inactivated by pulmonary surfactants; ventilated patients often have labile renal function, complicating dosing.
- Therapy sequencing: earlier, evidence‑based deployment of newer agents may improve survival in select high‑risk scenarios, provided stewardship controls are robust.
- On‑therapy resistance: continuous surveillance for emergence is essential, particularly in Pseudomonas and other highly adaptive organisms.
The trajectory is clear: innovation must be matched by delivery science, diagnostic depth and procurement reform. Stewardship in this era is less about denying access and more about placing the right drug, at the right exposure, in the right patient pathway-precisely when it has the best chance to work, and in line with the accountability frameworks that now sit above every hospital antibiotic order.
Related reading
